hydroxyzine has been researched along with Amphetamine-Related Disorders in 1 studies
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.
hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ling, W | 1 |
| Shoptaw, S | 1 |
| Hillhouse, M | 1 |
| Bholat, MA | 1 |
| Charuvastra, C | 1 |
| Heinzerling, K | 1 |
| Chim, D | 1 |
| Annon, J | 1 |
| Dowling, PT | 1 |
| Doraimani, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse[NCT00260481] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxyzine and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.
Topics: Adult; Amines; Amphetamine-Related Disorders; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug | 2012 |